Brief: Monte Rosa Therapeutics Q2 EPS USD -0.43
08/08/2024 12:00
Aug 08 (Reuters) - Monte Rosa Therapeutics Q2 operating expenses USD 37.337 million. * Q2 pretax profit USD -30.058 million * Q2 operating income USD -32.642 million * Q2 net income USD -30.31 million
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million